Related Experiment Videos
Allogeneic stem cell transplantation for renal cell carcinoma
1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892-1501, USA. childsr@nih.gov
Current Opinion in Urology
|August 9, 2001
Summary
Allogeneic stem cell transplantation shows promise for treating metastatic kidney cancer. This immunotherapy approach leverages donor T-cells to combat tumors, offering potential cures for patients unresponsive to other treatments.
Area of Science:
- Immunotherapy
- Oncology
- Hematology
Background:
- Metastatic kidney cancer has a poor prognosis despite recent immunotherapeutic advancements.
- Cytokine therapy and dendritic cell vaccines have shown limited success.
- Allogeneic stem cell transplantation is a potent immunotherapy for hematological malignancies.
Purpose of the Study:
- To investigate the potential of allogeneic stem cell transplantation for metastatic renal cell carcinoma.
- To explore the graft-versus-tumor effect in renal cell carcinoma.
- To review early clinical results of this investigational approach.
Main Methods:
- Review of studies on allogeneic stem cell transplantation for metastatic renal cell carcinoma.
- Analysis of non-myeloablative stem cell transplantation protocols.
- Evaluation of disease response and graft-versus-tumor effects.
Main Results:
- Metastatic disease regression observed following non-myeloablative stem cell transplantation.
- Renal cell carcinoma demonstrated susceptibility to graft-versus-tumor effect.
- Responses ranged from partial to complete, including in patients refractory to cytokine therapy.
Conclusions:
- Allogeneic stem cell transplantation is a viable immunotherapy for metastatic renal cell carcinoma.
- The graft-versus-tumor effect is a key mechanism in this treatment.
- Further clinical trials are warranted to optimize this approach.